We're developing the first longevity drugs for dogs.

Buck

Age 9

Our approach

Aging is the most significant modifiable risk factor for many degenerative and chronic diseases in adult dogs. Targeting the ways dogs age and decline over time may be one of the most effective and practical ways to increase their healthy lifespan.

At Loyal, our approach is to help dogs live longer and stay healthier as they age by developing drugs that target the underlying processes that lead to age-associated disease and disability.

drug programs in development

veterinary clinics in STAY clinical trial

1,317

dogs enrolled in STAY clinical trial

Illustration representing our approach to developing longevity drugs for dogs

Chase

Age 12

Abby

Age 13

LOY-002

Meet our lead drug for

Senior dogs

LOY-002 targets metabolic dysfunction, a core driver of the diseases many senior dogs experience as they age. By addressing the root cause, LOY-002 aims to extend lifespan and maintain quality of life for longer.

Target population

Dogs age 10+, 14+ lb

How it works

Improving age-associated metabolic dysfunction through a once-daily pill

FDA approval progress

2/3 major requirements completed. FDA approval not guaranteed.

RXE: preliminary efficacy data

Accepted

TAS: safety studies

Accepted

CMC: manufacturing

In progress

Abby

Age 13

We're developing a portfolio of aging therapeutics.

Explore all products

Dog owners

Veterinarians

Good news for senior dogs

We've hit a major milestone. LOY-002 just completed the second of three major requirements for FDA conditional approval. It's the clearest signal yet that a longevity drug for dogs could be available soon.

What this means for senior dogs